Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

A systemic complete response of metastatic melanoma to local radiation and immunotherapy.

Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA, Swetter SM, Knox SJ.

Transl Oncol. 2012 Dec;5(6):404-7. Epub 2012 Dec 1.

2.
3.

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

Weber J.

Oncologist. 2008;13 Suppl 4:16-25. doi: 10.1634/theoncologist.13-S4-16. Review.

4.

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M, Maio M.

Cancer Immunol Immunother. 2009 Aug;58(8):1297-306. doi: 10.1007/s00262-008-0642-y. Epub 2009 Jan 13.

PMID:
19139884
5.
6.

Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.

Lens M, Testori A, Ferucci PF.

Curr Top Med Chem. 2012;12(1):61-6. Review.

PMID:
22196270
7.

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.

Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD.

Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5. doi: 10.1073/pnas.0810114105. Epub 2008 Dec 12.

8.

Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.

Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, Zuber M, Jackson HM, Dimopoulos N, Tan BS, Hoos A, Luescher IF, Davis ID, Chen W, Cebon J.

Clin Cancer Res. 2009 Apr 1;15(7):2507-13. doi: 10.1158/1078-0432.CCR-08-2424. Epub 2009 Mar 24.

9.

Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.

Ridolfi L, Ridolfi R.

Hepatogastroenterology. 2002 Mar-Apr;49(44):335-9.

PMID:
11995445
10.

Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.

Sundstedt A, Celander M, Eriksson H, Törngren M, Hedlund G.

J Immunother. 2012 May;35(4):344-53. doi: 10.1097/CJI.0b013e318253ec25.

PMID:
22495392
11.

Ipilimumab (Yervoy) and the TGN1412 catastrophe.

Bakacs T, Mehrishi JN, Moss RW.

Immunobiology. 2012 Jun;217(6):583-9. doi: 10.1016/j.imbio.2011.07.005. Epub 2011 Jul 7. Review.

PMID:
21821307
12.

Ipilimumab in advanced melanoma: reports of long-lasting responses.

Farolfi A, Ridolfi L, Guidoboni M, Nicoletti SV, Piciucchi S, Valmorri L, Costantini M, Scarpi E, Amadori D, Ridolfi R.

Melanoma Res. 2012 Jun;22(3):263-70. doi: 10.1097/CMR.0b013e328353e65c.

PMID:
22516968
13.

Pathologic complete response of a solitary melanoma brain metastasis after local ablative radiation therapy: case report.

Register S, Clarke JW, Chaudhury AR, Lo SS.

Med Oncol. 2010 Dec;27(4):1208-11. doi: 10.1007/s12032-009-9360-3. Epub 2009 Nov 18.

PMID:
19921550
14.

Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab.

Andersen R, Nørgaard P, Al-Jailawi MK, Svane IM.

Oncoimmunology. 2014 Aug 3;3(8):e954506. eCollection 2014.

15.

Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?

Pennock GK, Waterfield W, Wolchok JD.

Am J Clin Oncol. 2012 Dec;35(6):606-11. doi: 10.1097/COC.0b013e318209cda9. Review.

PMID:
21336089
16.

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.

Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA.

Ann Surg Oncol. 2005 Dec;12(12):1005-16. Epub 2005 Oct 21.

17.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
18.

Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.

Simeone E, Ascierto PA.

J Immunotoxicol. 2012 Jul-Sep;9(3):241-7. doi: 10.3109/1547691X.2012.678021. Epub 2012 Apr 23. Review.

PMID:
22524673
19.

Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.

Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, Miller W, Payne R, Glenn L, Bageac A, Urba WJ.

Sci Transl Med. 2012 Jun 6;4(137):137ra74. doi: 10.1126/scitranslmed.3003649.

20.

[Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].

Lotem M, Merims S, Frank S, Ospovat I, Peretz T.

Harefuah. 2012 Oct;151(10):585-8, 604. Review. Hebrew.

PMID:
23316667
Items per page

Supplemental Content

Write to the Help Desk